About 119K results
GSK, Shingles
✕About this result- This title and these news articles are related to your search term(s).
- Articles come from a variety of sources across the web.
- Titles are algorithmically generated based on content related to your search term(s).
- People also ask
GSK (LSE:GSK) Poised for Growth with Strong Sales, …
WEB3 days ago · GSK (LSE:GSK) is navigating a dynamic environment marked by both opportunities and challenges. Recent highlights include a robust 13% sales growth and strategic innovations in R&D, contrasted...
Press releases | GSK
WEBBrowse GSK global press releases issued since 2009. Search them by keyword or browse by year/business category. Press releases issued by …
- Estimated Reading Time: 2 mins
GSK Announces Positive Topline Data on Co …
WEB4 days ago · PHILADELPHIA, September 18, 2024 -- (BUSINESS WIRE)--GSK plc (LSE/NYSE: GSK) today announced positive topline data from the phase 3 trial in adults 50 years and older evaluating the...
GSK Bets on Blood-Cancer Drug Comeback Amid Oncology Push
WEBSep 13, 2024 · GSK is betting that Blenrep--a blood-cancer treatment that U.S. drug regulators asked it to pull from the market in 2022--could get a second chance, part of a …
GSK makes a strong start to 2024 with improving …
WEBMay 1, 2024 · GSK reports strong performance and pipeline progress in Q1 2024, with sales up 10% and core EPS up 28%. The company updates its guidance and declares a dividend of 15p for Q1 2024.
Press releases | GSK US
WEBUS FDA approves expanded age indication for GSK’s AREXVY, the first respiratory syncytial virus (RSV) vaccine for adults aged 50-59 at increased risk.
GSK announces positive results from DREAMM-8 phase III trial for ...
WEBMar 7, 2024 · Blenrep (belantamab mafodotin) is an antibody-drug conjugate that showed significant progression-free survival and overall survival benefits in two phase III trials for …
GSK News
WEBStay updated on the latest news from GSK, a global healthcare company with innovative medicines, vaccines and consumer products.
US FDA approves GSK’s AREXVY, the world’s first respiratory …
WEBMay 3, 2023 · AREXVY is the first RSV vaccine for adults 60 and older, based on positive phase III trial data. It is expected to launch in the US before the 2023/24 RSV season …
GSK shares fall as US narrows age recommendation for RSV vaccines
WEBJun 27, 2024 · GSK shares fell more than 6 per cent on Thursday morning after US health officials recommended restricting the use of vaccines for respiratory syncytial virus, an …
